Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.
OBJECTIVE
Systemic combination chemotherapy is the only option for patients with unresectable hepatocellular carcinoma (HCC) not suitable for intra-arterial treatment. However, no systemic chemotherapy has been able to provide durable remission. The search for a new combination of drugs for HCC is significant. The combination of doxorubicin and paclitaxel shows promise in breast cancer therapy. This study was carried out to determine the synergistic effect of combined doxorubicin and paclitaxel in the two HCC cell lines: HepG2 and Huh7 in vitro and murine HCC H22-bearing BALB/c mice in vivo.


METHODS
The morphology of the two cell lines treated with drugs was photomicrographed. The 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide assay was used to determine the number of surviving cells. Cell cycle was evaluated by flow cytometry. Cell viability was measured by the ability of single cells to form colonies in vitro. Anti-tumor activities against subcutaneoulsy implanted solid tumor induced by H22 cells in mice were evaluated.


RESULTS
Our data demonstrated that the cytotoxicity produced by doxorubicin and paclitaxel was additive in HCC cells, while it was mainly held in the G2/M phase of the cell cycle by paclitaxel. In vivo anti-tumor activity assay also showed that the combination of the two drugs resulted in more significant tumor regression, compared to the single one.


CONCLUSIONS
The study may provide a new combination of cytotoxic drugs for HCC chemotherapy.
Jin
Cheng
C
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Li
Haimin
H
He
Yong
Y
He
Min
M
Bai
Ling
L
Cao
Yunxin
Y
Song
Wenjie
W
Dou
Kefeng
K
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage; D005434:Flow Cytometry; D016195:G2 Phase / Q000187:drug effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D017239:Paclitaxel / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004317:Doxorubicin; D017239:Paclitaxel
J Clin Oncol. 1994 Jun;12(6):1204-11
8201383
J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8
16234567
Chin Med J (Engl). 2008 Oct 20;121(20):1975-9
19080259
J Hepatol. 1990 Sep;11(2):181-4
2174933
N Engl J Med. 1995 May 11;332(19):1256-61
7708069
J Natl Cancer Inst Monogr. 1993;(15):141-7
7912520
Cancer Chemother Pharmacol. 2008 Apr;61(5):847-53
17609947
J Clin Oncol. 2008 Apr 20;26(12):1980-6
18421049
Surg Oncol Clin N Am. 2003 Jan;12(1):127-34
12735134
Am J Clin Oncol. 2006 Jun;29(3):267-75
16755180
Gut. 2002 Oct;51(4):459-62
12235060
Semin Oncol. 2001 Oct;28(5):514-20
11685744
Hepatogastroenterology. 2005 Jul-Aug;52(64):1083-6
16001634
Cancer Treat Rev. 1988 Mar;15(1):1-31
2834053
World J Gastroenterol. 2003 Apr;9(4):696-700
12679913
Transplant Proc. 2005 Mar;37(2):1254-6
15848687
Oncol Rep. 2007 May;17(5):1195-200
17390065
Expert Opin Investig Drugs. 2004 Dec;13(12):1555-68
15566313
Nat Genet. 2002 Aug;31(4):339-46
12149612
Eur J Cancer. 1998 Jul;34(8):1290-2
9849493
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Chin Med J (Engl). 2005 Oct 20;118(20):1688-94
16313753
Transplant Proc. 2002 Sep;34(6):2316-7
12270414
Lancet. 2003 Dec 6;362(9399):1907-17
14667750
Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):583-92
9486608
Ann Surg. 1993 Apr;217(4):375-84
8385442